Clinical trials: Stage I Liver Cancer
Breast Cancer, Metastatic Cancer
Biological Therapy in Treating Women With Breast Cancer That Has Spread to the Liver
RATIONALE: Biological therapy using a gene-modified virus that can make interleukin-12 may help the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00301106
- Testing
- adenovirus-mediated human interleukin-12
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Max Sung
Cancer Pain, Visceral Pain
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL).
- Conditions
- Cancer Pain, Visceral Pain, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract
- Trial name
- NCT04907643
- Testing
- PICO G2 4k
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- Cedars-Sinai Medical Center
Hepatocellular Carcinoma
A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients
Hepatocellular carcinoma (HCC) is a prevalent malignancy with great disease burden both in Taiwan and worldwide 1. Early stage HCC can be treated by surgical resection, radiofrequency ablation, embolization and liver…
- Trial name
- NCT05281926
- Testing
- Poly ICLC
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- National Taiwan University Hospital
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of ixabepilone in treating young…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00030108
- Testing
- ixabepilone
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hepatocellular Carcinoma
Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC)
The purpose of this phase I study is to determine the maximal tolerable dose (MTD) of thalidomide (THADO®) in combination with fixed dose of sorafenib (NEXAVAR®) for the treatment of advanced or metastatic HCC.
- Trial name
- NCT00971126
- Testing
- sorafenib (Nexavar®), thalidomide (Thado®)
- Where
- Taiwan
- Volunteers
- 3 people
- Sponsor
- National Health Research Institutes, Taiwan
Hepatocellular Carcinoma
Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)
The goal of this clinical trial is to evaluate the safety and efficacy of anti-GPC3 scFv-41BB-CD3ζ-tEGFR chimeric antigen receptor (CAR)-modified T (CAR-T) cells in treating patients with GPC3-positive advanced hepatocellular…
- Trial name
- NCT03084380
- Testing
- Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xinqiao Hospital of Chongqing
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant
This phase I trial studies the side effects and best dose of sorafenib tosylate in treating patients with liver cancer who have undergone a liver transplant.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
- Trial name
- NCT00844168
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Washington
Colorectal Cancer, Colorectal Neoplasms
Early Detection of Advanced Adenomas and Colorectal Cancer
This study aims to develop a highly sensitive, specific, and cost-effective blood assay for early detection of colorectal adenomas and cancer, using advanced machine learning and state-of-the-art biological analyses.
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Polyp, Colorectal Adenocarcinoma
- Trial name
- AACRC (NCT06342440)
- Testing
- DENEB
- Where
- 6 sites in United States, China and 3 more
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Hepatocellular Cancer, Cholangiocarcinoma
Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases
The main purpose of this study is to determine if high doses of radiation using proton beam can be given safely with low and acceptable side effects.
- Conditions
- Hepatocellular Cancer, Cholangiocarcinoma, Hepatic Metastases
- Trial name
- NCT00465023
- Testing
- Proton Beam Radiation
- Volunteers
- 16 people
- Sponsor
- Massachusetts General Hospital
Resectable Cholangiocarcinoma, Stage IB Intrahepatic Cholangiocarcinoma AJCC v8
Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer
This phase II trial studies how well gemcitabine, cisplatin, and nab-paclitaxel work before surgery in treating participants with high-risk bile duct cancer in the liver (intrahepatic cholangiocarcinoma).
- Conditions
- Resectable Cholangiocarcinoma, Stage IB Intrahepatic Cholangiocarcinoma AJCC v8, Stage II Intrahepatic Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8
- Trial name
- NCT03579771
- Testing
- Cisplatin, Gemcitabine, Nab-paclitaxel
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Emory University
Adrenocortical Carcinoma, Breast Cancer
Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer
RATIONALE: Biological therapies, such as tumor necrosis factor, may stimulate the immune system in different ways and stop tumor cells from growing.
- Conditions
- Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer
- Trial name
- NCT00436410
- Testing
- colloidal gold-bound tumor necrosis factor, electron microscopy, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Solid Tumor, Adult, Solid Tumor
Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent
This clinical trial is designed as a multi-center, open-label, dose-escalation, dose-expansion, phase 1 clinical trial and will be evaluating the safety and efficacy of PB101 in patients with advanced solid tumors who have…
- Conditions
- Solid Tumor, Adult, Solid Tumor, Gastric Cancer, Hepatocellular Carcinoma
- Trial name
- NCT06075849
- Testing
- PB101
- Where
- 3 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- Panolos Bioscience
Hepatocellular Carcinoma (HCC)
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
This is a multicenter, randomized, double-blind, parallel-controlled, phase I clinical study to evaluate the PK characteristics, safety, efficacy, and immunogenicity of HLX13 and US-sourced YERVOY® in patients with unresectable…
- Trial name
- NCT07176650
- Testing
- HLX13, Yervoy, OPDIVO
- Where
- 51 sites in United States, China
- Volunteers
- 246 people
- Sponsor
- Shanghai Henlius Biotech
HCC - Hepatocellular Carcinoma
QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma
This is a phase I trial to assess the safety and preliminary efficacy of QL1706 in Treating Advanced Hepatocellular Carcinoma Patients refractory to prior immunotherapy.
- Trial name
- QL1706 (NCT06822985)
- Testing
- QL1706
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Wan-Guang Zhang
Liver Cancer, Advanced Cancers
Hepatic Arterial Infusion (HAI) of Abraxane
The goal of this clinical research study is find the highest tolerated dose of Abraxane (nab-paclitaxel) that can be given directly into the liver of patients with advanced cancer that has spread to the liver.
- Conditions
- Liver Cancer, Advanced Cancers, Solid Tumors
- Trial name
- NCT00732836
- Testing
- HAI Abraxane, Hepatic Artery Catheter, IV Abraxane
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Liver Cancer, Hepatocellular Carcinoma
Proton Beam Therapy for Treatment of Hepatocellular Carcinoma
This study is designed to evaluate the possible benefits and side effects of the use of proton therapy for patients with hepatocellular carcinoma.
- Trial name
- NCT00614913
- Testing
- Proton radiation therapy
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Loma Linda University
Radiotherapy, Immunotherapy
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.
- Conditions
- Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis From Malignant Tumor of Liver
- Trial name
- NCT03589339
- Testing
- NBTXR3, SABR, Nivolumab
- Where
- 13 sites in United States
- Volunteers
- 145 people
- Sponsor
- Nanobiotix
Melanoma, Liver Metastasis
Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver
The goal of this clinical research is to find the highest tolerable dose of Abraxane (nab-paclitaxel) when given directly to the area where the cancer is located. The safety of this drug will also be studied.
- Trial name
- NCT00833807
- Testing
- Nab-Paclitaxel (Abraxane)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Stage IIIA Hepatocellular Carcinoma, Stage IIIB Hepatocellular Carcinoma
Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer
The purpose of this study is to identify maximum tolerated dose (MTD), that is, the highest dose of the study drug nivolumab that does not cause unacceptable side effects, for combination treatment of nivolumab and yttrium Y 90…
- Conditions
- Stage IIIA Hepatocellular Carcinoma, Stage IIIB Hepatocellular Carcinoma, Stage IIIC Hepatocellular Carcinoma, Stage IVA Hepatocellular Carcinoma
- Trial name
- NCT02837029
- Testing
- Laboratory Biomarker Analysis, Nivolumab, Yttrium Y 90 Glass Microspheres
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Northwestern University
Hepatocellular Carcinoma
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours…
- Trial name
- RHEA-1 (NCT06795022)
- Testing
- AZD9793 Intravenous (IV) monotherapy, AZD9793 Subcutaneous (SC) monotherapy
- Where
- 21 sites in United States, China and 5 more
- Volunteers
- 304 people
- Sponsor
- AstraZeneca